• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23365 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of robotic-assisted orthopedic surgery for knee and hip arthroplasty]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding two genetic variants of Zellweger spectrum disorder to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Assesment of artificial intelligence´s diagnostic yield and security in cardiac monitoring using insertable cardiac monitors]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Diagnostic accuracy of impulse oscillometry (IOS) compared to spirometry]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Radiofrequency echographic multi-spectrometry for bone mineral density assessment]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevance of adding a genetic variant of mucolipidosis type II to the carrier testing offer for people from the Saguenay-Lac-Saint-Jean, Charlevoix, and Haute-Côte-Nord regions]
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) Tunstall TSP – a system for receiving and processing personal alarm alerts
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) MoodPilot® digital diary
2024     Finnish Coordinating Center for Health Technology Assessment (FinCCHTA) DentView – a digital self-care guidance tool for oral health
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: carrier screening - disease selection, considerations, and ethical, psychosocial, sociocultural, organizational, and economic issues]
2024     Penn Medicine Center for Evidence-based Practice (CEP) Locking solutions for central venous catheters: 2024 update
2024     Penn Medicine Center for Evidence-based Practice (CEP) Communication interventions in healthcare that consider race and ethnicity
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Iontophoresis for primary palmar and plantar hyperhidrosis]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Artificial urinary sphincter post-prostatectomy]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Hybrid-knife endoscopic submucosal dissection]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal membrane oxygenation for acute respiratory distress syndrome and lung transplantation in adults]
2024     Canary Health Service [Cost-effectiveness of universal vaccination against pneumococcal disease with the new conjugate vaccines against 15 and 20 serotypes]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of STAT1 phosphorylation status by flow cytometry]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: initial evaluation of lung cancer patients for whom surgery is the first treatment – portrait of the situation in Québec from 2016 to 2019]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elranatamab (multiples Myelom) - Addendum zum Projekt A24-12]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Omaveloxolone (Friedreich’s ataxia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rozanolixizumab (myasthenia gravis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy – Second addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy - Addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Measurement and monitoring of pulmonary arterial pressure by means of implanted sensor for treatment optimization in heart failure stage NYHA III - Addendum to Project D23-02]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for talquetamab (multiple myeloma) - First addendum to Project A23-100]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone; previously untreated DLBCL) – Addendum to Project A23-141]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dostarlimab (endometrial cancer) - Addendum to Project A23-143]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (gastric and gastro-oesophageal junction adenocarcinoma, HER2-positive) – Addendum to Project A24-01]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for valoctocogene roxaparvovec: Review of the study protocol (Version 3.0) and statistical analysis plan (Version 3.0) – Fourth addendum to Project A22-20]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Letermovir (prophylaxis of CMV reactivation and disease after stem cell transplantation) - Addendum to Project A23-139]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etrasimod (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abaloparatide (osteoporosis, postmenopausal women) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third addendum to Commission A22-83]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gadopiclenol (contrast-enhanced magnetic resonance imaging) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabine/cedazuridine (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zilucoplan (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enalapril (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV): talquetamab (multiple myeloma)]
2024     NIHR Health Technology Assessment programme Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study
2024     NIHR Health Services and Delivery Research programme Digital First Primary Care for those with multiple long-term conditions: a rapid review of the views of stakeholders
2024     NIHR Health Services and Delivery Research programme Lessons for the UK on implementation and evaluation of breastfeeding support: evidence syntheses and stakeholder engagement
2024     NIHR Health Services and Delivery Research programme Community First Responders’ role in the current and future rural health and care workforce: a mixed-methods study
2024     NIHR Health Services and Delivery Research programme Using palliative care needs rounds in the UK for care home staff and residents: an implementation science study
2024     NIHR Health Services and Delivery Research programme Understanding how children and young people with chronic non-cancer pain and their families experience living with pain, pain management and services: a meta-ethnography
2024     NIHR Health Technology Assessment programme Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis
2024     NIHR Health Technology Assessment programme Treatment options for patients with pilonidal sinus disease: PITSTOP, a mixed-methods evaluation
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: imaging of the spine for the investigation of low back pain]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: integrating innovations into social and health services systems]
2024     NIHR Health Technology Assessment programme Reducing self-harm in adolescents: the RISA-IPD individual patient data meta-analysis and systematic review
2024     NIHR Health Technology Assessment programme Home-monitoring for neovascular age-related macular degeneration in older adults within the UK: the MONARCH diagnostic accuracy study
2024     NIHR Health Technology Assessment programme A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model
2024     NIHR Health Technology Assessment programme Devices for remote continuous monitoring of people with Parkinson’s disease: a systematic review and cost-effectiveness analysis
2024     NIHR Health Technology Assessment programme Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT
2024     National Institute for Health and Care Excellence (NICE) Artificial intelligence (AI)-derived software to help clinical decision making in stroke. NICE diagnostics guidance 57
2024     National Institute for Health and Care Excellence (NICE) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. NICE diagnostics guidance 58
2024     National Institute for Health and Care Excellence (NICE) GaitSmart rehabilitation exercise programme for gait and mobility issues. NICE medical technologies guidance 78
2024     National Institute for Health and Care Excellence (NICE) Kurin Lock for blood culture collection. NICE medical technologies guidance 77
2024     Health Technology Wales (HTW) FloSeal in the treatment of epistaxis
2024     Health Technology Wales (HTW) Artificial intelligence assisted tools for prostate cancer diagnosis using whole slide biopsy images
2024     Health Technology Wales (HTW) Artificial Intelligence (AI)-assisted endoscopy in the detection of gastrointestinal cancer and pre-cancerous lesions
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: major depressive disorder during pregnancy]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: intravesical treatment for bladder cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: initiating osteodensitometry following the assessment of fracture risk with the FRAX tool]
2024     Canary Health Service [Effectiveness, safety and cost-effectiveness of automated systems for detecting adverse drug reactions]
2024     Canary Health Service [Effectiveness, safety, and cost-effectiveness of out-of-hospital cardiac rehabilitation for ischemic heart disease or heart failure]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: reducing the carbon footprint of anesthetic agents inhaled in the operating room during general anesthesia - strategies and challenges to consider]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024     NIHR Health Technology Assessment programme Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews
2024     NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Can the postoperative routine of intravenous/oral antibiotics after acute appendectomy in children with perforated appendicitis be shortened?
2024     The Regional Health Technology Assessment Centre (HTA-centrum) Automated feedback based on digitalized follow-up of patients with unipolar depression receiving pharmacotherapy
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: judicious blood culture use]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment discussions: Does shared decision-making between doctor and patient regarding the choice of treatment lead to better results?]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cognitive behavioural therapy: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflavone: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Clonidine: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2024     NIHR Health Technology Assessment programme Laparoscopic cholecystectomy versus conservative management for adults with uncomplicated symptomatic gallstones: the C-GALL RCT
2024     NIHR Health Services and Delivery Research programme Service innovations for people with multiple long-term conditions: reflections of a rapid evaluation team
2024     NIHR Health Technology Assessment programme Comparison of surgical or non-surgical management for non-acute anterior cruciate ligament injury: the ACL SNNAP RCT
2024     NIHR Health Services and Delivery Research programme Improving support and planning ahead for older people with learning disabilities and family carers: a mixed-methods study
2024     NIHR Health Technology Assessment programme Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model
2024     NIHR Health Technology Assessment programme Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation
2024     Scottish Health Technologies Group (SHTG) FDG PET dementia imaging - SHTG Recommendation
2024     Scottish Health Technologies Group (SHTG) Artificial intelligence supported clinician review of chest x-rays from patients with suspected lung cancer - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Genotype testing to guide antibiotic use and prevent hearing loss in babies - SHTG Assessment
2024     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) - SHTG Assessment
2024     Penn Medicine Center for Evidence-based Practice (CEP) Interventions to prevent aspiration pneumonia in non-ventilated hospitalized patients
2024     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of tezepelumab (Tezspire)]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: tumor biomarkers related to the management of people with cholangiocarcinoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: Acute myeloid leukemia treatment algorithm]
2024     Health Information and Quality Authority (HIQA) Magnetic resonance imaging-guided radiotherapy: Protocol for an evidence review to inform generic justification